|
Diabetic macular edema
|
0.100 |
Biomarker
|
disease |
BEFREE |
Fas Ligand (FasL), Macrophage Inflammatory Proteins (MIP)-1α, Regulated on Activation Normal T Cell Expressed and Secreted (RANTES) and Vascular Endothelial Growth Factor (VEGF) were increased in DME at baseline versus controls and decreased after SMPL treatments (p < 0.05).
|
31296907 |
2019 |
|
Diabetic macular edema
|
0.100 |
Biomarker
|
disease |
BEFREE |
Anti-Fumarase Antibody as a Predictor of Functional Efficacy of Anti-VEGF Therapy for Diabetic Macular Edema.
|
30807637 |
2019 |
|
Diabetic macular edema
|
0.100 |
Biomarker
|
disease |
BEFREE |
Characterization of the Systemic Findings of Patients Undergoing Initiation of Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema in Routine Clinical Practice.
|
30640391 |
2019 |
|
Diabetic macular edema
|
0.100 |
Biomarker
|
disease |
BEFREE |
These findings suggest the benefit of simultaneous inhibition of angiopoietin-2 and VEGF-A with faricimab for patients with DME.
|
30905643 |
2019 |
|
Diabetic macular edema
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our study described the 2-year real-life outcome of anti-vascular endothelial growth factor treatment of diabetic macular edema and age-related macular degeneration.
|
31617403 |
2019 |
|
Diabetic macular edema
|
0.100 |
Biomarker
|
disease |
BEFREE |
Serum pro-inflammatory factors as predictors of persistent diabetic macular oedema with limited anatomic response to anti-VEGF: association with intravitreal injection treatment profiles in real-world setting.
|
31742896 |
2019 |
|
Diabetic macular edema
|
0.100 |
Biomarker
|
disease |
BEFREE |
Using this model, we investigated the retinal responses to VEGF-Trap (Aflibercept), an anti-angiogenic agent recognizing ligands of VEGF receptors 1 and 2 that possesses regulatory approval for the treatment of neovascular age-related macular degeneration, macular edema secondary to retinal vein occlusion and diabetic macular edema.
|
31550048 |
2019 |
|
Diabetic macular edema
|
0.100 |
Biomarker
|
disease |
BEFREE |
There is no association between the studied VEGF-A SNVs and the responses to IVR therapy in DME.
|
29030794 |
2018 |
|
Diabetic macular edema
|
0.100 |
Biomarker
|
disease |
BEFREE |
Anti-vascular endothelial growth factor treatment is the first-line therapy in the treatment of center-involving diabetic macular edema.
|
29494727 |
2018 |
|
Diabetic macular edema
|
0.100 |
Biomarker
|
disease |
BEFREE |
Early Response to Anti-Vascular Endothelial Growth Factor and Two-Year Outcomes Among Eyes With Diabetic Macular Edema in Protocol T.
|
30077569 |
2018 |
|
Diabetic macular edema
|
0.100 |
Biomarker
|
disease |
BEFREE |
Under-treatment is a major problem of DME anti- vascular endothelial growth factor therapy under real life conditions.
|
30288700 |
2018 |
|
Diabetic macular edema
|
0.100 |
Biomarker
|
disease |
BEFREE |
Plasma Vascular Endothelial Growth Factor Concentrations after Intravitreous Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema.
|
29525602 |
2018 |
|
Diabetic macular edema
|
0.100 |
Biomarker
|
disease |
BEFREE |
A literature review was conducted using the PubMed database on 1 February 2018 to identify studies evaluating the efficacy of anti-VEGF and dexamethasone (DEX) implants for DME.
|
30246026 |
2018 |
|
Diabetic macular edema
|
0.100 |
Biomarker
|
disease |
BEFREE |
COMPLIANCE AND ADHERENCE OF PATIENTS WITH DIABETIC MACULAR EDEMA TO INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY IN DAILY PRACTICE.
|
29068914 |
2018 |
|
Diabetic macular edema
|
0.100 |
Biomarker
|
disease |
BEFREE |
OPTICAL COHERENCE TOMOGRAPHY BASELINE PREDICTORS FOR INITIAL BEST-CORRECTED VISUAL ACUITY RESPONSE TO INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT IN EYES WITH DIABETIC MACULAR EDEMA: The CHARTRES Study.
|
28613220 |
2018 |
|
Diabetic macular edema
|
0.100 |
Biomarker
|
disease |
BEFREE |
Visual Outcomes Based on Early Response to Anti-Vascular Endothelial Growth Factor Treatment for Diabetic Macular Edema.
|
29316563 |
2018 |
|
Diabetic macular edema
|
0.100 |
Biomarker
|
disease |
BEFREE |
We postulate that targeting downstream effector proteins of VEGF and other mediators that are directly involved in the regulation of BBB and BRB integrity provide more attractive and safer treatment options for vasogenic cerebral edema and diabetic macular edema.
|
30231925 |
2018 |
|
Diabetic macular edema
|
0.100 |
Biomarker
|
disease |
BEFREE |
Short-Term Results of Intravitreal Triamcinolone Acetonide Combined with Cataract Surgery for Diabetic Macular Edema in Japan: In the Era of Anti-Vascular Endothelial Growth Factor Therapy.
|
29621780 |
2018 |
|
Diabetic macular edema
|
0.100 |
Biomarker
|
disease |
BEFREE |
As compared with no-DR patients, vascular endothelial growth factor was only moderately elevated in DME patients (P>0.05), but significantly elevated in Hr-PDR patients (P<0.05).
|
29303154 |
2018 |
|
Diabetic macular edema
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Levels of IL-2, IL-8, PlGF, and VEGF were significantly elevated in DME patients (p = 0.007, p < 0.001, p < 0.001, and p = 0.004 respectively).
|
30204781 |
2018 |
|
Diabetic macular edema
|
0.100 |
Biomarker
|
disease |
BEFREE |
Anti-Vascular Endothelial Growth Factor Treatment for Diabetic Macular Edema in a Real-World Clinical Setting.
|
30098350 |
2018 |
|
Diabetic macular edema
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study found that serous retinal detachment and disorganization of retinal inner layers were associated with different treatment responses to anti-vascular endothelial growth factor therapy in patients with diabetic macular edema.
|
28406860 |
2018 |
|
Diabetic macular edema
|
0.100 |
Biomarker
|
disease |
BEFREE |
Flavoprotein Fluorescence Correlation with Visual Acuity Response in Patients Receiving Anti-VEGF Injection for Diabetic Macular Edema.
|
30159113 |
2018 |
|
Diabetic macular edema
|
0.100 |
Biomarker
|
disease |
BEFREE |
Eyes with diabetic macular edema and a history of ≥ 20 intravitreal anti-vascular endothelial growth factor (aflibercept and/or ranibizumab) injections were included in this retrospective study.
|
28767550 |
2018 |
|
Diabetic macular edema
|
0.100 |
Biomarker
|
disease |
BEFREE |
Vision Outcomes Following Anti-Vascular Endothelial Growth Factor Treatment of Diabetic Macular Edema in Clinical Practice.
|
29684329 |
2018 |